ALPMY Stock UPDATES Astellas Pharma Inc (ALPMY) 14.4050 08/30/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Astellas Pharma Inc (ALPMY) 14.4050 $ALPMY

Astellas-Basilea's Isavuconazole Accepted for EU Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 4:30PM CDT
Astellas Pharma, Inc. (ALPMY) and Basilea's isavuconazole has been accepted for review in the EU for the treatment of invasive aspergillosis and mucormycosis.

AVEO Pharmaceuticals Posts Narrower-than-Expected Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 8:30AM CDT
AVEO Pharmaceuticals reported a second-quarter 2014 loss of 35 cents per share.

Medivation Jumps on Q2 Earnings Beat, Outlook Encourages - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 11:10AM CDT
Medivation Inc. (MDVN) posted earnings of 60 cents per share.

Astellas Up on Pipeline Update, Oncology in Focus (revised) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 3:07PM CDT
Astellas Pharma, Inc. (ALPMY) provided a comprehensive overview of its initiatives towards innovation, research and development and its corporate strategy.

Astellas' Isavuconazole Gets QIDP for Invasive Candidiasis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 17, 4:50PM CDT
Astellas Pharma, Inc.'s (ALPMY) isavuconazole received Qualified Infectious Disease Product (QIDP) designation from the FDA for treating invasive candidiasis.

Astellas Up on Pipeline Update, Oncology in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 16, 2:03PM CDT
Astellas Pharma, Inc.'s (ALPMY) shares gained 2.5% following the company's update on its pipeline and corporate strategy late last week.

Astellas Seeks FDA Nod for Fungal Infection Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 4:30PM CDT
Astellas Pharma, Inc. (ALPMY) has filed an NDA with the FDA for isavuconazole for the treatment of invasive aspergillosis and mucormycosis.

ARIAD Candidate in Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 5:10PM CDT
ARIAD started phase II pivotal study on AP26113 for non-small cell lung cancer (NSCLC) in patients who had previously been treated with Pfizer's Xalkori (crizotinib).

AstraZeneca's Forxiga Approved in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 25, 3:45PM CDT
AstraZeneca announced that its type II diabetes drug, Forxiga, has been approved by the Japanese Ministry of Health, Labour and Welfare.

Japan Approves Medivation/Astellas' Xtandi - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 25, 12:50PM CDT
Prostate cancer treatment, Xtandi, which is already approved in more than 35 countries is now approved in Japan.

AVEO Regains AV-203 Rights from Biogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 5:10PM CDT
AVEO Oncology (AVEO) recently announced that it has regained worldwide rights of candidate AV-203 from Biogen Idec (BIIB).

Medivation, Inc: Fast Growing Drugs That May Become Blockbusters
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 21, 1:30PM CDT
Blockbuster status -- the gold medal term awarded to therapies racking up sales of more than $1 billion per year -- is the Holy Grail for drug developers. Arguably, it's the chance to discover blockbusters that fuels industry R&D spend and...

Medivation-Astellas Seek Xtandi Label Expansion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 3:20PM CDT
The companies are looking to get Xtandi approved for the chemo-naive patient population.

AVEO Q4 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 8:10AM CDT
AVEO Pharmaceuticals reported a fourth quarter 2013 loss of 32 cents per share.

Was Medivation's Quarter a Disaster?
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 03, 5:30PM CST
Medivation's  sell-off last week reflects investor disappointment in guidance for sales of Xtandi, a prostate cancer drug prescribed to patients who fail to respond to chemotherapy. Sales of Xtandi jumped double digit percentages...

Medivation Swings to Earnings in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 8:30AM CST
Xtandi's approval in the pre-chemo setting would boost sales significantly.

Biotech Stock Roundup: Regeneron's Eylea Impresses, Gilead Files for Next HCV Drug - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 19, 8:27AM CST
The Medicines Co. was also in the news with an FDA advisory panel refusing to back the company's antiplatelet agent, Cangrelor.

Primco Files Preliminary Form 14c to Increase Authorized Shares
PR Newswire - Tue Feb 18, 11:30PM CST
Primco Management Inc. (OTCQB: PMCM), a fully integrated multi-media entertainment and real estate development company today announced that the Company has filed Form 14c, as required by the Securities and Exchange Commission, informing shareholders of an increase in the authorized to 25 billion common shares as a reserve requirement for possible future conversion issuances, in accordance with contractual obligations to convertible debt holders based on the recent low stock price of $0.0001. The increase will further allow Primco to have sufficient shares available for equity funding, and/or for potential acquisitions which the Board of Directors may determine is in the best interest of the shareholders.

AVEO/Astellas Terminate Agreement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 18, 3:30PM CST
AVEO Pharma and Astellas announced their decision to terminate their agreement for the development and commercialization of tivozanib.

Vical Q4 Loss Narrows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 11:10AM CST
Vical's fourth quarter loss narrows




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Elisity’s Texas Water Pilot Puts IonQ’s Deal in View

Updated Category News Views 208

Water-system security is not a place for chest-thumping Elisity’s role in Texas Project Watershed 250 lands on a problem that is painfully concrete: water and wastewater utilities have to keep pumps, treatment systems and plant operations running while trying to close cybersecurity gaps. That is a tougher job than selling another dashboard to a corporate IT department....

Continue Reading
Sectra's RSNA AI Pitch Centers on Workflow, Not Hype

Updated Category News Views 6

Radiology has heard enough grand AI promises to fill a hospital basement, which makes Sectra's RSNA 2026 message refreshingly grounded. The Swedish imaging IT and cybersecurity company is putting its weight behind the unglamorous part of adoption: fitting AI into the daily diagnostic machinery without handing clinicians another awkward system to babysit. That is where...

Continue Reading
Berlin Heals Puts Microcurrent Therapy to a Real Test

Updated Category News Views 17

A silent electrical signal is heading into the sort of trial that separates intriguing ideas from credible medical evidence. Berlin Heals Holding AG has initiated C-MIC IV, an international randomized, double-blind, sham-controlled study of its implanted microcurrent therapy for symptomatic heart failure. The first patient has already been implanted in Kragujevac, Serbia....

Continue Reading
Hanon's BMW Thermal Win Matters Beyond the Trophy Case Today

Updated Category News Views 96

A 16-Kilogram Box Just Grabbed the Auto Supply Chain’s Attention Hanon Systems did not win these two 2026 PACE honors by polishing up some old hose-and-valve package. Its Highly Integrated Cooling Entity, or HICE, is aimed right at a stubborn electric-vehicle problem: keeping a vehicle’s thermal systems controlled without turning the architecture into a sprawling,...

Continue Reading
Utility Global’s India Steel Move Needs Hard Numbers

Updated Category News Views 104

Steel decarbonization announcements can sound enormous before a single bolt gets tightened. Utility Global says it plans to deploy its first industrial H2Gen project in India with Tata Steel, and that is plainly worth watching. Tata Steel is a serious industrial name, India is a consequential steel market, and any technology that can credibly lower emissions from heavy...

Continue Reading
Holiday Grease Advice Shows Utility Work Up Close Today

Updated Category News Views 117

Butter and pan drippings are mundane right until they become a backed-up kitchen line on a crowded holiday afternoon. New Jersey American Water's Nov. 17, 2026 reminder is not glamorous utility news, and frankly it is not trying to be. It is a practical warning: fats, oils and grease can cool, harden and accumulate in household pipes and farther along the wastewater...

Continue Reading
LONGi's Solar-Storage Push Faces Africa's Cost Wall

Updated Category News Views 22

A vaccine refrigerator humming through a blackout is more meaningful than another climate-conference slogan. That was the useful thread running through LONGi's November 13 COP31 side event in Antalya, Türkiye: solar and storage are not merely hardware for remote communities. When designed, financed and maintained properly, they can keep clinics, water pumps and other...

Continue Reading
LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 156

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading
Gozney Brings in Armin Boehm for a Global Growth Push

Updated Category News Views 67

A pizza oven company has just made a very grown-up management move. Gozney appointed Armin Boehm as Global President, effective from October 31, putting an experienced consumer-brand operator beside founder, designer and CEO Tom Gozney at a moment when the business says it is becoming a global omnichannel operation. This is not the sort of announcement that comes with...

Continue Reading
Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 194

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading

Top 5 Most Recently Viewed Articles

Natus Medical Unveils Advanced EMG Software for Enhanced Use

Updated Category News Views 116

Natus Medical's Latest EMG Software Release Natus Medical Incorporated is excited to announce the launch of its newest edition of the Natus Elite EMG software. This software continues to set a high standard in the neurodiagnostic field, delivering both familiarity and reliability that users have come to expect. What makes this release particularly noteworthy is the...

Continue Reading
Toll Brothers Unveils New Luxury Homes in August Park Community

Updated Category News Views 231

Your Dream Home Awaits at August Park Toll Brothers, Inc., a leader in luxury home building, recently announced the launch of an exciting new community known as Toll Brothers at August Park. This neighborhood promises not just high-end living but also a tranquil environment perfect for families and individuals seeking a peaceful lifestyle. Located in a serene area, this...

Continue Reading
Johnny Bigg Expands Presence with New Concessions in Retail

Updated Category News Views 678

Johnny Bigg's Exciting Expansion into Retail Johnny Bigg, a popular fashion brand dedicated to big and tall men, continues to grow its presence in the retail landscape. Recently, the company took a significant step by launching concessions in selected Belk stores. This move marks an important milestone for Johnny Bigg, showcasing its commitment to making fashionable...

Continue Reading
Exploring Sound Investments With Warren Buffett's Wisdom

Updated Category News Views 284

Warren Buffett stood tall as the legendary investor who transformed Berkshire Hathaway into a $1 trillion powerhouse. Back then, this valuation didn’t hinge on flashy products or industry domination. It was all about Buffett’s knack for hunting down stocks that consistently outperformed the market. Berkshire Hathaway's Focused Portfolio: Goldmine or Gimmick? At one...

Continue Reading
Understanding KPIs: A Key to Effective Life Science Marketing

Updated Category News Views 205

Understanding the Importance of KPIs in Life Science Marketing In today's fast-paced life science sector, it's crucial for organizations to utilize data-driven decisions to enhance customer engagement. However, surprisingly, thirty-two percent of marketing and analytics teams in the life sciences report either not knowing about or not using key performance indicators...

Continue Reading